Company intelligence / Profile preview

LigaTrap Technologies

Raleigh, North Carolina, United Statesligatrap.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

LigaTrap Technologies developed proprietary affinity ligands and chromatography resins enabling high-purity antibody and viral vector purification. Their products were adopted by academic labs and industry clients worldwide. In April 2025, all IP, assets, staff, and ongoing business were transferred to the new company ChromaGenix under BioProcess360 Partners. No clinical results are relevant since the company did not develop therapeutics.

Modalities: ProteinAntibodyViral vectorBiologic
Industry: Chemicals & Materials

Partnerships

Participated in international consortia; specific partners not named in public sources.

Beyond the preview

Go deeper on LigaTrap Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LigaTrap Technologies.

Explore the full profile